A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 24 Aug 2016
At a glance
- Drugs Ixabepilone (Primary) ; Cyclophosphamide; Doxorubicin; Paclitaxel
- Indications Early breast cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 30 Jun 2012 Planned number of patients changed from 300 to 330 as reported by European Clinical Trials Database.
- 21 Jan 2011 New source identified and integrated (Clinical Trials Registry - India).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History